Jazz Pharmaceuticals (JAZZ) Gains Put Its Valuation Story Back In Focus

Jazz Pharmaceuticals (JAZZ) has drawn investor attention after recent trading left the share price at $240.57, with mixed short term moves but strong longer term total returns shaping the current debate.

The recent 30-day share price return of down 5.39% contrasts with a 90-day gain of 4.66% and a year-to-date share price return of 38.94%, while the 1-year total shareholder return of 85.91% suggests that momentum for Jazz Pharmaceuticals has been building rather than fading.

Compare Jazz Pharmaceuticals’ recent momentum with a curated group of peers by scanning 29 high quality undervalued stocks that share solid fundamentals and may be setting up for their next big move.

Bulls point to Jazz Pharmaceuticals’ recent double digit total returns and ongoing profitability, while bears flag the pullback over the past month and execution risks. Which side does the current valuation really support next?

Most Popular Narrative: 17% Undervalued

Jazz Pharmaceuticals is currently trading at $240.57 against a widely followed fair value estimate of $289.45, so the key question is whether its product pipeline and portfolio breadth justify that gap.

The expected approval and launches of multiple therapies (dordaviprone for H3 K27M-mutant diffuse glioma and Zepzelca in first-line maintenance for small cell lung cancer) are set to drive new revenue streams and capitalize on unmet needs in rare cancers, supporting topline growth and improved earnings consistency.

See why 33 investors see Jazz Pharmaceuticals as 17% undervalued.

Result: Fair Value of $289.45 (UNDERVALUED)

Still, patent expiries and rising generic competition, together with high debt from past acquisitions, could quickly challenge the current Jazz Pharmaceuticals valuation story.

Find out about the key risks to this Jazz Pharmaceuticals narrative.

Another View On Jazz Pharmaceuticals’ Valuation

The story looks different when the focus shifts to the P/E ratio. Jazz Pharmaceuticals trades on 16.6x earnings, which is slightly higher than the US pharmaceuticals average of 16.5x, yet well below peers at 38x and an estimated fair ratio of 25x. Is that a margin of safety or a signal the market is cautious?

See what the numbers say about this price in more detail with See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

Mixed views on Jazz Pharmaceuticals so far. If you want to move fast and build your own informed stance, start with the 4 key rewards and 2 important warning signs.

Looking For More Investment Ideas Beyond Jazz Pharmaceuticals?

Do not stop your research with Jazz Pharmaceuticals. Broaden your watchlist using targeted screeners that surface different types of opportunities other investors may be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com